The Center for Pharmaceutical Research (CPR) is a privately owned clinical research center specializing in providing phase II, IIb, III ,IIIb and IV clinical research services for the pharmaceutical, nutritional, and medical device industries.

John E. Ervin, MD, FACP, FACR founded The Center for Pharmaceutical Research in 1986, and has been the president, Medical Director and Principal Investigator for the center. Since its inception, CPR has conducted more than 250 trials in most areas of medical and surgical subspecialties (osteoarthritis, rheumatoid arthritis, chronic pain, irritable bowel, migraine, constipation, psoriasis, dermatology, acid reflux, heartburn, benign prostatic hyperplasia, hypertension, hyperlipidemia, cholesterol, diabetes, osteoporosis, obesity, insomnia, wound care, orthopedics, gynecology and urology, etc.).

Dr. Ervin is a founding member of The Alliance for Multispecialty Research (www.amrllc.com), a board member and current president for the Society of Principle Investigators (www.sopi.org), a charter board member of The Alliance for Better Bone Health, a Fellow of the American College of Physicians, a Founding Fellow of the American College of Rheumatology, and has spent two years on the planning committee of The American Academy of Pharmaceutical Physicians and helped build their investigator certification exam. The Center for Pharmaceutical Research was recently recognized by the Kansas City Business Journal as one of "The Best Places to Work in Kansas City".

CPR has two primary missions, each equally important: To provide optimum and ethical medical care to our patients, and provide the combination of rapid enrollment and high quality, clean research data to the pharma industry. All the site's RNs have been FBI background checked for restricted drug administration.

CPR utilizes the sites Clinasyst database of over 6000 patients who have indicated an over 95% patient satisfaction with their previous studies and over 90% request to be considered for future studies. Dr. Ervin also utilizes his private group practice database of over 16,000 patients to notify them of upcoming or enrolling studies via an IRB-approved letter, and utilizes many subinvestigators with private practice patient databases. This results in rapid over-enrollment of most studies before use of more expensive utilization of advertisement media.

We have established a HIPAA-compliant set of guidelines and training program, and are also FAA-compliant/trained. All coordinators and coordinator assistants undergo extensive training and testing.